Literature DB >> 23032196

Acute heart failure: perspectives from a randomized trial and a simultaneous registry.

Justin A Ezekowitz1, Jia Hu, Diego Delgado, Adrian F Hernandez, Padma Kaul, Rolland Leader, Guy Proulx, Sean Virani, Michel White, Shelley Zieroth, Christopher O'Connor, Cynthia M Westerhout, Paul W Armstrong.   

Abstract

BACKGROUND: Randomized controlled trials (RCT) are limited by their generalizability to the broader nontrial population. To provide a context for Acute Study of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, we designed a complementary registry to characterize clinical characteristics, practice patterns, and in-hospital outcomes of acute heart failure patients. METHODS AND
RESULTS: Eligible patients for the registry included those with a principal diagnosis of acute heart failure (ICD-9-CM 402 and 428; ICD-10 I50.x, I11.0, I13.0, I13.2) from 8 sites participating in ASCEND-HF (n=697 patients, 2007-2010). Baseline characteristics, treatments, and hospital outcomes from the registy were compared with ASCEND-HF RCT patients from 31 Canadian sites (n=465, 2007-2010). Patients in the registry were older, more likely to be female, and have chronic respiratory disease, less likely to have diabetes mellitus: they had a similar incidence of ischemic HF, atrial fibrillation, and similar B-type natriuretic peptide levels. Registry patients had higher systolic blood pressure (registry: median 132 mm Hg [interquartile range 115-151 mm Hg]; RCT: median 120 mm Hg [interquartile range 110-135 mm Hg]) and ejection fraction (registry: median 40% [interquartile range 27-58%]; RCT: median 29% [interquartile range 20-40 mm Hg]) than RCT patients. Registry patients presented more often via ambulance and had a similar total length of stay as RCT patients. In-hospital mortality was significantly higher in the registry compared with the RCT patients (9.3% versus 1.3%,P<0.001), and this remained after multivariable adjustment (odds ratio 6.6, 95% CI 2.6-16.8, P<0.001).
CONCLUSIONS: Patients enrolled in a large RCT of acute heart failure differed significantly based on clinical characteristics, treatments, and inpatient outcomes from contemporaneous patients participating in a registry. These results highlight the need for context of RCTs to evaluate generalizability of results and especially the need to improve clinical outcomes in acute heart failure. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00475852.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23032196     DOI: 10.1161/CIRCHEARTFAILURE.112.968974

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  9 in total

1.  Heart failure: Registry data reveal disparities in care.

Authors:  Alexandra King
Journal:  Nat Rev Cardiol       Date:  2012-10-23       Impact factor: 32.419

Review 2.  Addressing the Heterogeneity of Heart Failure in Future Randomized Trials.

Authors:  Annamaria Iorio; Andrea Pozzi; Michele Senni
Journal:  Curr Heart Fail Rep       Date:  2017-06

Review 3.  Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy.

Authors:  Kalkidan Bishu; Margaret M Redfield
Journal:  Curr Heart Fail Rep       Date:  2013-09

Review 4.  Similarities and differences in patient characteristics between heart failure registries versus clinical trials.

Authors:  Abhinav Sharma; Justin A Ezekowitz
Journal:  Curr Heart Fail Rep       Date:  2013-12

5.  Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF).

Authors:  Justin A Ezekowitz; Mohua Podder; Adrian F Hernandez; Paul W Armstrong; Randall C Starling; Christopher M O'Connor; Robert M Califf
Journal:  BMJ Open       Date:  2016-03-17       Impact factor: 2.692

6.  A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results.

Authors:  Tessa Kennedy-Martin; Sarah Curtis; Douglas Faries; Susan Robinson; Joseph Johnston
Journal:  Trials       Date:  2015-11-03       Impact factor: 2.279

7.  Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations.

Authors:  Amelia J Averitt; Chunhua Weng; Patrick Ryan; Adler Perotte
Journal:  NPJ Digit Med       Date:  2020-05-11

8.  Eligibility for cardiac resynchronization therapy in patients hospitalized with heart failure.

Authors:  Joanna Osmanska; Nathaniel M Hawkins; Mustafa Toma; Andrew Ignaszewski; Sean A Virani
Journal:  ESC Heart Fail       Date:  2018-06-25

9.  Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis.

Authors:  Xiao Zhang; Shihui Fu; Rui Meng; Yu Ren; Ye Shang; Lei Tian
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.